Compare Stocks: BPMX, BNTC, CMPX, and LRMR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTC Benitec Biopharma	$12.47	$12.73	$9.85 ▼ $16.76	$428.34M	0.28	189,840 shs	103,167 shs
BPMX Biopharmx		$0.00	$0.25 ▼ $6.30	$111.86M	N/A	2.15 million shs	336,508 shs
CMPX Compass Therapeutics	$2.40	$2.19	$1.61 ▼ $6.88	$432.21M	0.92	3.20 million shs	2.57 million shs
LRMR Larimar Therapeutics	$4.01	$3.87	$2.71 ▼ $6.42	$416.56M	0.81	1.05 million shs	641,495 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTC Benitec Biopharma	0.00%	-7.49%	+6.49%	+15.25%	-5.82%
BPMX Biopharmx	0.00%	0.00%	0.00%	0.00%	0.00%
CMPX Compass Therapeutics	0.00%	0.00%	+25.65%	+8.11%	-31.23%
LRMR Larimar Therapeutics	0.00%	-4.07%	+4.97%	+14.25%	+10.77%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTC Benitec Biopharma	$12.47	$12.73	$9.85 ▼ $16.76	$428.34M	0.28	189,840 shs	103,167 shs
BPMX Biopharmx		$0.00	$0.25 ▼ $6.30	$111.86M	N/A	2.15 million shs	336,508 shs
CMPX Compass Therapeutics	$2.40	$2.19	$1.61 ▼ $6.88	$432.21M	0.92	3.20 million shs	2.57 million shs
LRMR Larimar Therapeutics	$4.01	$3.87	$2.71 ▼ $6.42	$416.56M	0.81	1.05 million shs	641,495 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTC Benitec Biopharma	0.00%	-7.49%	+6.49%	+15.25%	-5.82%
BPMX Biopharmx	0.00%	0.00%	0.00%	0.00%	0.00%
CMPX Compass Therapeutics	0.00%	0.00%	+25.65%	+8.11%	-31.23%
LRMR Larimar Therapeutics	0.00%	-4.07%	+4.97%	+14.25%	+10.77%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNTC Benitec Biopharma	2.60	Moderate Buy	$24.80	98.88% Upside
BPMX Biopharmx	0.00	N/A	N/A	N/A
CMPX Compass Therapeutics	2.88	Moderate Buy	$11.77	390.38% Upside
LRMR Larimar Therapeutics	3.10	Buy	$11.67	190.94% Upside

Current Analyst Ratings Breakdown

Latest BPMX, BNTC, CMPX, and LRMR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2026	CMPX Compass Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$4.00 ➝ $6.00
8/5/2026	LRMR Larimar Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$12.00 ➝ $11.00
7/28/2026	BNTC Benitec Biopharma	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$16.00
7/28/2026	BNTC Benitec Biopharma	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$16.00
7/17/2026	BNTC Benitec Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	CMPX Compass Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	LRMR Larimar Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/2/2026	LRMR Larimar Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$10.00
7/1/2026	CMPX Compass Therapeutics	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$5.00
6/30/2026	LRMR Larimar Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
6/30/2026	LRMR Larimar Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$7.00 ➝ $5.00

(Data available from 8/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNTC Benitec Biopharma	N/A	N/A	N/A	N/A	$3.71 per share	N/A
BPMX Biopharmx	N/A	N/A	N/A	N/A	N/A	N/A
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	$1.11 per share	N/A
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	$0.94 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNTC Benitec Biopharma	-$37.92M	-$1.14	N/A	N/A	N/A	N/A	-34.82%	-34.11%	9/28/2026 (Estimated)
BPMX Biopharmx	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CMPX Compass Therapeutics	-$66.49M	-$0.40	N/A	N/A	N/A	N/A	-38.71%	-34.72%	11/4/2026 (Estimated)
LRMR Larimar Therapeutics	-$165.67M	-$1.95	N/A	N/A	N/A	N/A	-137.39%	-97.65%	11/5/2026 (Estimated)

Latest BPMX, BNTC, CMPX, and LRMR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/28/2026	Q4 2026	BNTC Benitec Biopharma	-$0.26	N/A	N/A	N/A	N/A	N/A
8/6/2026	Q2 2026	CMPX Compass Therapeutics	-$0.1107	-$0.13	-$0.0193	-$0.13	($0.60) million	N/A
8/4/2026	Q2 2026	LRMR Larimar Therapeutics	-$0.3815	-$0.30	+$0.0815	-$0.30	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNTC Benitec Biopharma	N/A	N/A	N/A	N/A	N/A
BPMX Biopharmx	N/A	N/A	N/A	N/A	N/A
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	N/A
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNTC Benitec Biopharma	N/A	56.82	56.82
BPMX Biopharmx	N/A	N/A	N/A
CMPX Compass Therapeutics	N/A	11.22	11.22
LRMR Larimar Therapeutics	N/A	4.70	4.70

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNTC Benitec Biopharma	52.19%
BPMX Biopharmx	N/A
CMPX Compass Therapeutics	68.43%
LRMR Larimar Therapeutics	91.92%

Insider Ownership

Company	Insider Ownership
BNTC Benitec Biopharma	4.80%
BPMX Biopharmx	N/A
CMPX Compass Therapeutics	18.70%
LRMR Larimar Therapeutics	4.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNTC Benitec Biopharma	20	34.35 million	32.71 million	No Data
BPMX Biopharmx	17	18.28 million	N/A	Not Optionable
CMPX Compass Therapeutics	20	180.09 million	146.41 million	Not Optionable
LRMR Larimar Therapeutics	30	103.88 million	99.73 million	Optionable

BPMX, BNTC, CMPX, and LRMR Headlines

Recent News About These Companies

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Consensus Rating of "Buy" from Analysts

2 hours ago | americanbankingnews.com

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Consensus Recommendation of "Buy" from Brokerages

2 hours ago | marketbeat.com

ADAR1 Capital Management LLC Makes New Investment in Larimar Therapeutics, Inc. $LRMR

August 26, 2026 | marketbeat.com

Larimar’s Phase 3 Friedreich’s Ataxia Trial Puts Nomlabofusp in the Investor Spotlight

August 21, 2026 | tipranks.com

Hennion & Walsh Asset Management Inc. Purchases New Position in Larimar Therapeutics, Inc. $LRMR

August 13, 2026 | marketbeat.com

Dimensional Fund Advisors LP Purchases 470,968 Shares of Larimar Therapeutics, Inc. $LRMR

August 13, 2026 | marketbeat.com

Renaissance Technologies LLC Has $3.33 Million Position in Larimar Therapeutics, Inc. $LRMR

August 9, 2026 | marketbeat.com

Regulatory and Manufacturing Risks Cloud Larimar Therapeutics’ Accelerated Approval Path for Nomlabofusp

August 7, 2026 | theglobeandmail.com

Larimar Therapeutics (LRMR) to Announce Earnings on Thursday

August 6, 2026 | marketbeat.com

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Average Recommendation of "Buy" from Analysts

August 6, 2026 | marketbeat.com

Wedbush Cuts Larimar Therapeutics (NASDAQ:LRMR) Price Target to $11.00

August 5, 2026 | marketbeat.com

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update

August 4, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR

July 23, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Larimar Therapeutics, Inc. - LRMR

July 21, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR

July 16, 2026 | prnewswire.com

Larimar Therapeutics (LRMR) Submits Initial Module of BLA For Nomlabofusp Therapy

July 16, 2026 | finance.yahoo.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR

July 14, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR

July 9, 2026 | prnewswire.com

Larimar Therapeutics (NASDAQ:LRMR) Director Buys 50,000 Shares

July 9, 2026 | insidertrades.com

LRMR Stock Edges Up After Hours After Director Purchases Shares Worth About $167,000

July 8, 2026 | finance.yahoo.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR

July 7, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BPMX, BNTC, CMPX, and LRMR Company Descriptions

Benitec Biopharma NASDAQ:BNTC

$12.47 0.00 (0.00%)

Closing price 08/28/2026 04:00 PM Eastern

Extended Trading

$12.48 +0.01 (+0.12%)

As of 03:59 AM Eastern

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

Biopharmx NYSEAMERICAN:BPMX

BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC). Its clinical-stage product candidates include BPX01, a topical antibiotic gel that has completed Phase II clinical trials for the treatment of inflammatory lesions of acne; BPX04, a topical antibiotic, which is in pre-Phase II feasibility study for the treatment of inflammatory lesions of rosacea; BPX02, a development stage product candidate for aesthetic dermatology applications; and BPX03, a molecular iodine tablet, which has completed pre-Phase III clinical trial for the treatment of periodic breast pain associated with FBC and cyclic mastalgia. The company serves pharmaceutical companies; physician's practices, including obstetricians and gynecologists, dermatologists, and general practitioners; and retail customers through retail sales channels and/or pharmacy outlets. It has collaboration and license agreement with Iogen LLC to develop molecular iodine formulations; and collaboration and supply agreement with NuTech Medical, Inc. to develop products in the field of dermatology. The company is headquartered in Menlo Park, California.

Compass Therapeutics NASDAQ:CMPX

$2.40 0.00 (0.00%)

Closing price 08/28/2026 04:00 PM Eastern

Extended Trading

$2.42 +0.02 (+0.83%)

As of 04:00 AM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Larimar Therapeutics NASDAQ:LRMR

$4.01 0.00 (0.00%)

Closing price 08/28/2026 04:00 PM Eastern

Extended Trading

$4.07 +0.06 (+1.37%)

As of 04:27 AM Eastern

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BPMX, BNTC, CMPX, and LRMR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BPMX, BNTC, CMPX, and LRMR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BPMX, BNTC, CMPX, and LRMR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BPMX, BNTC, CMPX, and LRMR Company Descriptions

Benitec Biopharma NASDAQ:BNTC

Biopharmx NYSEAMERICAN:BPMX

Compass Therapeutics NASDAQ:CMPX

Larimar Therapeutics NASDAQ:LRMR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BPMX, BNTC, CMPX, and LRMR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BPMX, BNTC, CMPX, and LRMR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BPMX, BNTC, CMPX, and LRMR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BPMX, BNTC, CMPX, and LRMR Company Descriptions

Benitec Biopharma NASDAQ:BNTC

Biopharmx NYSEAMERICAN:BPMX

Compass Therapeutics NASDAQ:CMPX

Larimar Therapeutics NASDAQ:LRMR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools